Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 3/20 | 0.36 |
| ▸ | NQO2 | P16083 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397871 | 0.85 | KDM4E (0.40) | AOC3ALDH1A1HSD17B10TDP1KMT2A | |
| SCHEMBL1443963 | 0.79 | AOC3 (0.46) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL16735524 | 0.79 | AOC3 (0.46) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL1443961 | 0.79 | AOC3 (0.46) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL2210181 | 0.79 | KMT2A (0.43) | AOC3ALDH1A1HSD17B10TDP1KMT2A | |
| SCHEMBL1579496 | 0.78 | TDP1 (0.46) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL881447 | 0.77 | NQO2 (0.45) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL2210040 | 0.77 | AOC3 (0.51) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL22589288 | 0.77 | ALDH1A1 (0.44) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL2571759 | 0.77 | ALDH1A1 (0.44) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131539-B1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | PECSI TUDOMANYEGYETEM (HU) | 2018-12-05 | — | — | EP | claimed |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-12-09 | — | — | US | disclosed |
| US-12428408-B2 | Fused heterocyclic mescaline derivatives | Enveric Biosciences Canada Inc. (CA) | 2025-09-30 | — | — | US | disclosed |
| US-20240116907-A1 | FUSED HETEROCYCLIC MESCALINE DERIVATIVES | Enveric Biosciences Canada Inc. (CA) | 2024-04-11 | — | — | US | disclosed |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2023-07-06 | — | — | US | disclosed |
| EP-3596067-B1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-06-07 | — | — | EP | disclosed |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) | 2023-03-07 | — | — | US | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109492-A1 | PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS | GOSSAMER BIOSERVICES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| EP-2342179-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | Semmelweis Egyetem (HU) | 2011-07-13 | — | — | EP | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
| US-6645975-B1 | Reducing, deprotecting and optionally alkylating chemical intermediates to form 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naphtho(1,2,3-de)isoquinoline, used as dopamine receptor agonists | PURDUE RESEARCH FOUNDATION | 2003-11-11 | — | — | US | disclosed |
| US-5948817-A | Polycyclic ethyl alkylamide melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1998038991-A1 | POLYCYCLIC ETHYL ALKYLAMIDE MELATONERGIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116907-A1 | FUSED HETEROCYCLIC MESCALINE DERIVATIVES | UGT2B7, CYP3A5, CYP2C19 | AOC3 725/4885ALDH1A1 252/4885HSD17B10 1425/4885 |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOX1, AOC3 | AOC3 3/4885ALDH1A1 44/4885HSD17B10 926/4885 |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | AOC3 3674/4885ALDH1A1 2424/4885HSD17B10 4154/4885 |
| US-20230212157-A1 | PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCC5, ABCC1 | AOC3 3554/4885ALDH1A1 1738/4885HSD17B10 2018/4885 |
| US-12428408-B2 | Fused heterocyclic mescaline derivatives | UGT2B7, CYP3A5, CYP2C19 | AOC3 725/4885ALDH1A1 252/4885HSD17B10 1425/4885 |
| US-12492193-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC1 | AOC3 3554/4885ALDH1A1 1738/4885HSD17B10 2018/4885 |
| US-11597723-B2 | Pyrazole derivatives for the treatment of cystic fibrosis | CFTR, ABCC5, ABCC3 | AOC3 3545/4885ALDH1A1 1717/4885HSD17B10 2007/4885 |
| US-20100113519-A1 | 1,5-Dideoxy-1,5-imino-D-glucitol Compounds | HEXD, GALE, GBA1 | AOC3 862/4885ALDH1A1 321/4885HSD17B10 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.